
|Articles|July 31, 2006
Fourth indication approved for gemcitabine
Women with recurrent ovarian cancer will now have a new therapy option. Gemcitabine (Gemzar, Lilly) has been approved for use in combination with carboplatin for advanced ovarian cancer that has relapsed at least six months after initial therapy.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Trump Executive Order Set to Reclassify Marijuana, Improve CBD Access
2
From Policy to Practice: Elevating Pharmacy’s Role in Quality and Patient Safety
3
Trial Approvals Face Delays During COVID-19 Pandemic
4
Scripted for Her: HRT Black Box Removal
5

















































































































